Pharma Foods International Co Ltd
TSE:2929
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharma Foods International Co Ltd's latest stock split occurred on Jan 28, 2015
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, Pharma Foods International Co Ltd traded at 1627 per share. Afterward, the share price was about 770.7487.
The adjusted shares began trading on Jan 28, 2015. This was Pharma Foods International Co Ltd's 2nd stock split, following the previous one in Jul 29, 2013.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
|
Apr 24, 2026
|
L
|
La Comer SAB de CV
OTC:LCMRF
|
115-for-114
x1.0087719298246
|
2.4715 2.4341 USD | 2.45 2.45 USD |
CUE
3902
MMI
Pharma Foods International Co Ltd
Glance View
Pharma Foods International Co., Ltd. engages in the development and sale of functional food materials. The company is headquartered in Kyoto, Kyoto-Fu and currently employs 293 full-time employees. The company went IPO on 2006-06-12. The firm operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The firm is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.
